| 000 | 01351 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250518025857.0 | ||
| 264 | 0 | _c20200323 | |
| 008 | 202003s 0 0 eng d | ||
| 022 | _a2044-6055 | ||
| 024 | 7 |
_a10.1136/bmjopen-2018-025161 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRezk, Mark | |
| 245 | 0 | 0 |
_aNone _h[electronic resource] |
| 260 |
_bBMJ open _c03 2019 |
||
| 300 |
_ae025161 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAndrogen Antagonists _xtherapeutic use |
| 650 | 0 | 4 |
_aBiomarkers, Tumor _xmetabolism |
| 650 | 0 | 4 | _aCohort Studies |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aGene Expression Regulation, Neoplastic |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aKallikreins _xmetabolism |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 |
_aProstate-Specific Antigen _xmetabolism |
| 650 | 0 | 4 |
_aProstatic Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aSurvival Rate |
| 700 | 1 | _aChandra, Ashish | |
| 700 | 1 | _aAddis, Daniel | |
| 700 | 1 | _aMøller, Henrik | |
| 700 | 1 | _aYoussef, Mina | |
| 700 | 1 | _aDasgupta, Prokar | |
| 700 | 1 | _aYamamoto, Hide | |
| 773 | 0 |
_tBMJ open _gvol. 9 _gno. 3 _gp. e025161 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1136/bmjopen-2018-025161 _zAvailable from publisher's website |
| 999 |
_c29459154 _d29459154 |
||